JP2008535477A5 - - Google Patents

Download PDF

Info

Publication number
JP2008535477A5
JP2008535477A5 JP2007557212A JP2007557212A JP2008535477A5 JP 2008535477 A5 JP2008535477 A5 JP 2008535477A5 JP 2007557212 A JP2007557212 A JP 2007557212A JP 2007557212 A JP2007557212 A JP 2007557212A JP 2008535477 A5 JP2008535477 A5 JP 2008535477A5
Authority
JP
Japan
Prior art keywords
seq
polypeptide
egfr
antibody
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007557212A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008535477A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2006/006751 external-priority patent/WO2006091899A2/en
Publication of JP2008535477A publication Critical patent/JP2008535477A/ja
Publication of JP2008535477A5 publication Critical patent/JP2008535477A5/ja
Pending legal-status Critical Current

Links

JP2007557212A 2005-02-24 2006-02-23 上皮成長因子受容体変異 Pending JP2008535477A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65626305P 2005-02-24 2005-02-24
PCT/US2006/006751 WO2006091899A2 (en) 2005-02-24 2006-02-23 Epidermal growth factor receptor mutations

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2012049012A Division JP2012149070A (ja) 2005-02-24 2012-03-06 上皮成長因子受容体変異

Publications (2)

Publication Number Publication Date
JP2008535477A JP2008535477A (ja) 2008-09-04
JP2008535477A5 true JP2008535477A5 (https=) 2009-04-09

Family

ID=36579263

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2007557212A Pending JP2008535477A (ja) 2005-02-24 2006-02-23 上皮成長因子受容体変異
JP2012049012A Pending JP2012149070A (ja) 2005-02-24 2012-03-06 上皮成長因子受容体変異

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2012049012A Pending JP2012149070A (ja) 2005-02-24 2012-03-06 上皮成長因子受容体変異

Country Status (15)

Country Link
US (2) US7981605B2 (https=)
EP (1) EP1851243A2 (https=)
JP (2) JP2008535477A (https=)
KR (1) KR20070106029A (https=)
CN (1) CN101208354A (https=)
AU (2) AU2006216477A1 (https=)
BR (1) BRPI0607235A2 (https=)
CA (1) CA2601936C (https=)
CR (1) CR9390A (https=)
EA (1) EA013617B1 (https=)
IL (1) IL185210A0 (https=)
MX (1) MX2007009963A (https=)
NO (1) NO20074826L (https=)
WO (1) WO2006091899A2 (https=)
ZA (1) ZA200707379B (https=)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101313702B1 (ko) * 2005-02-03 2013-10-04 와이어쓰 제피티니브 및/또는 에를로티니브 내성암 치료용 약제학적 조성물
EP2505591A1 (en) 2005-02-11 2012-10-03 Memorial Sloan-Kettering Cancer Center Methods and compositions for detecting a drug resistant EGFR mutant
US12366585B2 (en) 2006-05-18 2025-07-22 Caris Mpi, Inc. Molecular profiling of tumors
US9090693B2 (en) * 2007-01-25 2015-07-28 Dana-Farber Cancer Institute Use of anti-EGFR antibodies in treatment of EGFR mutant mediated disease
BRPI0808551B1 (pt) 2007-03-01 2022-04-05 Symphogen A/S Composições de anticorpo para o receptor do fator de crescimento antiepidérmico recombinante, molécula de ligação bi-específica e composição farmacêutica que os compreende
US9340601B2 (en) 2007-03-01 2016-05-17 The Board Of Trustees Of The Leland Stanford Junior University Splice variants of the EGF receptor
PT2412828E (pt) * 2007-03-13 2013-08-02 Amgen Inc Mutações k-ras e b-raf e terapia com anticorpos anti-egfr
GB2453173A (en) * 2007-09-28 2009-04-01 Dxs Ltd Polynucleotide primers
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
CL2009000843A1 (es) * 2008-04-11 2009-07-24 Galaxy Biotech Llc Metodo para tratar cancer en un paciente que comprende la administracion de un primer agente que es inhibidor de factor de crecimiento de hepatocito (hgf) en combinacion con un segundo agente que es inhibidor de una ruta de senalizacion celular diferente de la ruta hgf/cmet.
BRPI0914790A2 (pt) 2008-06-17 2015-10-20 Wyeth Llc uso de um composto de vinorelbina e um composto de hki-272, composição farmacêutica e produto e kit para o tratamento de neoplasma
ATE544063T1 (de) * 2008-07-17 2012-02-15 Koninkl Philips Electronics Nv Nanoporenvorrichtung und verfahren zur nukleinsäureanalyse
WO2010022736A2 (en) 2008-08-29 2010-03-04 Symphogen A/S Recombinant anti-epidermal growth factor receptor antibody compositions
CN101445832B (zh) * 2008-12-23 2011-09-14 广州益善生物技术有限公司 Pik3ca基因突变的检测探针、液相芯片及其检测方法
EP3722810A3 (en) * 2009-02-11 2021-01-13 Caris MPI, Inc. Molecular profiling of tumors
EP2475789A4 (en) * 2009-09-09 2013-12-18 Quintiles Transnat Corp METHOD FOR PREDICTING THE RESPONSIBILITY OF A DISEASE OR A SLEEPING TO A RECEPTOR SYRINOIN INHIBITORY BY ANALYSIS OF MUTATIONS IN PIK3CA
JP5891172B2 (ja) * 2010-07-07 2016-03-22 エーザイ・アール・アンド・ディー・マネジメント株式会社 正常乳腺上皮細胞からの腫瘍細胞の製造方法
US20120164641A1 (en) * 2010-12-22 2012-06-28 Roche Molecular Systems, Inc. Methods and Compositions for Detecting Mutation in the Human Epidermal Growth Factor Receptor Gene
US8628773B2 (en) 2011-04-07 2014-01-14 Amgen Inc. Antigen binding proteins
AU2012253525B2 (en) * 2011-05-10 2016-09-22 Brunangelo Falini Hairy cell leukemia biomarkers and methods of using same
EP2554551A1 (en) * 2011-08-03 2013-02-06 Fundacio Institut mar d'Investigacions Médiques (IMIM) Mutations in the epidermal growth factor receptor gene
US20140005119A1 (en) * 2012-06-28 2014-01-02 Case Western Reserve University COMPOSITIONS AND METHODS FOR INHIBITING THE ACTIVITY OF P110a MUTANT PROTEINS
CN105264084A (zh) * 2013-01-14 2016-01-20 中央研究院 静默egfr表达的脱氧核糖核酸酶
CN103739713B (zh) * 2013-12-10 2016-03-09 吴炯 一种新型诱导肺瘤细胞凋亡的融合蛋白及其应用
US9067998B1 (en) 2014-07-15 2015-06-30 Kymab Limited Targeting PD-1 variants for treatment of cancer
US9017678B1 (en) 2014-07-15 2015-04-28 Kymab Limited Method of treating rheumatoid arthritis using antibody to IL6R
US8945560B1 (en) 2014-07-15 2015-02-03 Kymab Limited Method of treating rheumatoid arthritis using antibody to IL6R
US8883157B1 (en) 2013-12-17 2014-11-11 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
US9034332B1 (en) 2014-07-15 2015-05-19 Kymab Limited Precision medicine by targeting rare human PCSK9 variants for cholesterol treatment
US9045545B1 (en) 2014-07-15 2015-06-02 Kymab Limited Precision medicine by targeting PD-L1 variants for treatment of cancer
GB2521355A (en) * 2013-12-17 2015-06-24 Kymab Ltd Human targets I
US8986691B1 (en) 2014-07-15 2015-03-24 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
US9914769B2 (en) 2014-07-15 2018-03-13 Kymab Limited Precision medicine for cholesterol treatment
WO2015092393A2 (en) * 2013-12-17 2015-06-25 Kymab Limited Human targets
US9023359B1 (en) 2014-07-15 2015-05-05 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
US9045548B1 (en) 2014-07-15 2015-06-02 Kymab Limited Precision Medicine by targeting rare human PCSK9 variants for cholesterol treatment
US8980273B1 (en) 2014-07-15 2015-03-17 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
US9150660B1 (en) 2014-07-15 2015-10-06 Kymab Limited Precision Medicine by targeting human NAV1.8 variants for treatment of pain
US9139648B1 (en) 2014-07-15 2015-09-22 Kymab Limited Precision medicine by targeting human NAV1.9 variants for treatment of pain
CN105779480B (zh) * 2016-03-24 2020-03-20 成都康景生物科技有限公司 一种携带多位点突变型egfr新抗原基因的重组腺相关病毒载体及构建方法和应用
RU2769282C2 (ru) 2016-06-20 2022-03-30 Кимаб Лимитед Анти-PD-L1 и IL-2 цитокины
EP3534947A1 (en) 2016-11-03 2019-09-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
US9980967B1 (en) 2017-03-16 2018-05-29 National Chiao Tung University Method for overcoming drug resistance of EGFR mutation and cancerous stemness of human non-small cell lung carcinoma
CN108047308A (zh) * 2018-02-02 2018-05-18 天津亨佳生物科技发展有限公司 一种治疗肿瘤的抗原肽链组及其在药物中的应用
CN108047309A (zh) * 2018-02-07 2018-05-18 天津亨佳生物科技发展有限公司 一种治疗肿瘤的抗原肽链组及其在药物中的应用
CN108250268A (zh) * 2018-02-08 2018-07-06 天津亨佳生物科技发展有限公司 一种治疗肿瘤的抗原肽链组及其在药物中的应用
CN108409832A (zh) * 2018-03-07 2018-08-17 天津亨佳生物科技发展有限公司 一种治疗肿瘤的抗原肽链组及其在药物中的应用
CN108218960A (zh) * 2018-03-07 2018-06-29 天津亨佳生物科技发展有限公司 一种治疗肿瘤的抗原肽链组及其在药物中的应用
CN108218959A (zh) * 2018-03-07 2018-06-29 天津亨佳生物科技发展有限公司 一种治疗肿瘤的抗原肽链组及其在药物中的应用
CN108218961A (zh) * 2018-03-19 2018-06-29 天津亨佳生物科技发展有限公司 一种治疗肿瘤的抗原肽链组及其在药物中的应用
CN108440649A (zh) * 2018-05-31 2018-08-24 天津亨佳生物科技发展有限公司 一种治疗肿瘤的抗原肽链组及其在药物中的应用
CN108752424A (zh) * 2018-06-04 2018-11-06 天津亨佳生物科技发展有限公司 一种治疗肿瘤的抗原肽链组及其在药物中的应用
CN108440650A (zh) * 2018-06-04 2018-08-24 天津亨佳生物科技发展有限公司 一种治疗肿瘤的抗原肽链组及其在药物中的应用
CN108440651A (zh) * 2018-06-08 2018-08-24 天津亨佳生物科技发展有限公司 一种治疗肿瘤的抗原肽链组及其在药物中的应用
TW202019421A (zh) * 2018-07-31 2020-06-01 大陸商蘇州亞盛藥業有限公司 Bcl-2/Bcl-xL抑制劑與化療藥物的組合及其應用
CN109485721A (zh) * 2018-11-23 2019-03-19 杜学明 一种获得肿瘤特异性t细胞受体的方法
RU2706116C1 (ru) * 2018-12-26 2019-11-14 Государственное бюджетное учреждение здравоохранения Московской области "Московский областной научно-исследовательский клинический институт им. М.Ф. Владимирского" (ГБУЗ МО МОНИКИ им. М.Ф. Владимирского) Способ прогнозирования течения аденокарциномы легкого
KR102370550B1 (ko) * 2019-01-11 2022-03-08 주식회사 진캐스트 Egfr 돌연변이 검출을 위한 dna 중합효소 및 이를 포함하는 키트
WO2020145754A1 (ko) * 2019-01-11 2020-07-16 주식회사 진캐스트 유전자 변이 특이성이 증가된 dna 중합효소를 이용한 질량분석법
KR102310819B1 (ko) * 2019-01-11 2021-10-12 주식회사 진캐스트 Tert 돌연변이 검출을 위한 dna 중합효소 및 이를 포함하는 키트
BR112021016149A2 (pt) 2019-02-26 2021-10-13 Janssen Biotech, Inc. Terapias de combinação e estratificação de pacientes com anticorpos biespecíficos anti-egfr/c-met
US11879013B2 (en) 2019-05-14 2024-01-23 Janssen Biotech, Inc. Combination therapies with bispecific anti-EGFR/c-Met antibodies and third generation EGFR tyrosine kinase inhibitors
US11850248B2 (en) 2019-05-14 2023-12-26 Yuhan Corporation Therapies with 3rd generation EGFR tyrosine kinase inhibitors
EP4005593A4 (en) * 2019-07-24 2023-08-16 Sinocelltech Ltd. MULTIVARIABLE DOSING METHOD FOR USE IN THE TREATMENT OF HIGH EGFR EXPRESSION CANCER
JP7783182B2 (ja) 2020-02-12 2025-12-09 ヤンセン バイオテツク，インコーポレーテツド ｃ－ＭＥＴエクソン１４スキッピング変異を有する患者の治療

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7838216B1 (en) * 1986-03-05 2010-11-23 The United States Of America, As Represented By The Department Of Health And Human Services Human gene related to but distinct from EGF receptor gene
EP0491007B1 (en) * 1989-09-08 1996-03-13 The Johns Hopkins University Structural alterations of the egf receptor gene in human gliomas
US20010046686A1 (en) * 2000-03-10 2001-11-29 Wong Albert J. Sensitive detection of wild-type and mutant EGFR by specific ELISA assays in any biological sample
US20050277118A1 (en) * 2002-09-11 2005-12-15 Roth Richard B Methods for identifying subjects at risk of melanoma and treatments thereof
ES2425749T3 (es) * 2004-03-31 2013-10-17 The General Hospital Corporation Método para determinar la respuesta del cáncer a tratamientos dirigidos al receptor del factor de crecimiento epidérmico
EP3042964A1 (en) * 2004-06-04 2016-07-13 Genentech, Inc. Egfr mutations
DK1771482T3 (da) * 2004-07-22 2014-10-20 Genentech Inc HER2-antistofsammensætning
US7442507B2 (en) * 2005-01-24 2008-10-28 New York University School Of Medicine Methods for detecting circulating mutant BRAF DNA
JP5154406B2 (ja) * 2005-04-13 2013-02-27 アステックス、セラピューティックス、リミテッド 医薬化合物
CA2612183C (en) 2005-06-28 2015-08-11 Genentech, Inc. Egfr and kras mutations

Similar Documents

Publication Publication Date Title
JP2008535477A5 (https=)
US7514226B2 (en) Antibody pair screening methods
JP6239503B2 (ja) 新規な抗ｃｘｃｒ４抗体並びに癌の検出および診断のためのその使用
JP6989927B2 (ja) リン酸化アルファ－シヌクレインを検出するための方法
TW201207396A (en) Novel antibody for the diagnosis and/or prognosis of cancer
JP7156622B2 (ja) 前立腺癌検出のための組成物と方法
JP2019508694A (ja) 腎疾患及び歯周疾患を検出及び診断するための方法及び組成物
CN112851818A (zh) 针对d-二聚体的结合蛋白及其应用和检测d-二聚体的方法
CN107001453A (zh) 结合人p53线性表位的抗体及其诊断应用
WO2015072686A1 (ko) 햅텐 및 이에 결합하는 항체를 레퍼런스 항체로 이용하는 면역학적 측정 방법 및 상기 레퍼런스 항체를 이용한 면역학적 측정장치
CN112920275A (zh) 可特异性结合sST2的结合蛋白、试剂和试剂盒
JP6977105B2 (ja) Ｉｇｆ−１ｒ抗体および癌の診断のためのその使用
CN113004405B (zh) 一种包含NT-proBNP抗原结合结构域的分离的结合蛋白
CN112920272A (zh) 抗cTnI的蛋白和检测cTnI的方法
JPH11506940A (ja) ミスマッチ修復タンパク質の抗体による検出
CN112898430A (zh) Ca242的结合蛋白及其应用、检测方法和试剂盒
CN113004411A (zh) 可特异性结合ckmb的结合蛋白、其应用以及检测ckmb的方法
CN112940130A (zh) 能够特异性结合mpo的结合蛋白、其用途、试剂、试剂盒和检测mpo的方法
CN107709362B (zh) Igf-1r抗体及其用于癌症诊断的用途
JP2024513880A (ja) 免疫組織化学法およびｋｉｒ３ｄｌ２特異的薬剤
CN118725112B (zh) 抗人sCD14-ST蛋白的单克隆抗体及其应用
KR102688094B1 (ko) Cobll1 단백질 특이 항체 또는 이의 항원 결합 단편, 및 이의 용도
CN111018973A (zh) 一种抗人心肌肌钙蛋白i的重组抗体
TW202428605A (zh) 抗體表徵方法
WO2025025731A1 (zh) 一种适用于免疫组化检测cd228的诊断抗体